Stealth Biotherapeutics Announces SBT-272 Data Updates And Orphan Drug Designation For Treatment Of Amyotrophic Lateral Sclerosis

November 01, 2022 11:42 AM GMT | By Reuters
Follow us on Google News:

Nov 1 (Reuters) - Stealth BioTherapeutics Corp:

* STEALTH BIOTHERAPEUTICS ANNOUNCES SBT-272 DATA UPDATES AND ORPHAN DRUG DESIGNATION FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)

* STEALTH BIOTHERAPEUTICS CORP - SBT-272 PHASE 1 SAFETY AND TOLERABILITY DATA SUPPORT FURTHER CLINICAL DEVELOPMENT Source text for Eikon: Further company coverage:


Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.



Top LSE Listed Companies